Hugel Aesthetics, the South Korean injectable manufacturer, is expanding its U.S. commercial footprint with a dedicated direct sales force for Letybo (its botulinum toxin) and a new K-TOX campaign. The move signals serious intent to compete head-to-head with AbbVie's Botox and Galderma's Dysport in the American market.
Business & M&A
Hugel Aesthetics Builds U.S. Direct Sales Force for Letybo and K-TOX Campaign
South Korean toxin maker invests in commercial infrastructure to challenge AbbVie and Galderma in the U.S. market.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Hugel is building direct U.S. sales infrastructure to challenge AbbVie and Galderma in the toxin market.
Letybo has gained traction in Asia and Europe on the strength of rapid onset (24–48 hours) and a favorable diffusion profile. A direct sales model in the U.S. is capital-intensive but allows Hugel to control messaging, pricing, and rebate strategy—critical levers in a market where Allergan and Galderma have long dominated through MSO partnerships and loyalty programs. For independent practices, this means a third credible toxin option with potential incentives to switch.
Source: original report ↗
Frequently asked questions
What is Letybo and how does it compare to Botox and Dysport?
Letybo is a botulinum toxin made by South Korean manufacturer Hugel Aesthetics. It has a rapid onset of 24–48 hours and a favorable diffusion profile, positioning it as a third credible alternative to AbbVie's Botox and Galderma's Dysport in the U.S. market.
Why is Hugel building a direct sales force in the U.S.?
A direct sales model allows Hugel to control messaging, pricing, and rebate strategy without relying on MSO partnerships, giving them competitive leverage against Allergan and Galderma's established loyalty programs. While capital-intensive, it enables independent practices to access a new toxin option with potentially better incentives.
What is the K-TOX campaign?
K-TOX is Hugel's new marketing campaign launching alongside their U.S. direct sales force expansion for Letybo. The campaign is part of their strategy to build brand awareness and challenge the market dominance of Botox and Dysport.
Is Letybo available to independent med spas and practices?
Yes. Hugel's direct sales model specifically targets independent practices as an alternative to the MSO-dominated distribution networks that have historically favored Botox and Dysport. This creates a new purchasing option for practices seeking competitive toxin pricing and rebate structures.
How fast does Letybo work compared to other botulinum toxins?
Letybo has a rapid onset of 24–48 hours, which is competitive with other premium botulinum toxins on the market. This quick onset, combined with its favorable diffusion profile, is a key selling point for Hugel in Asia and Europe.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.